A new drug that has passed safety tests in adults is likely to be effective against the aggressive childhood cancer neuroblastoma, Cancer Research UK-funded scientists have found.
Their findings are published in The Journal of Clinical Investigation today (October 5), with plans to make the drug available to children through a clinical trial by the end of the year.
The drug, called fadraciclib, was jointly discovered by scientists at The Institute of Cancer Research (ICR), London, in collaboration with the US company Cyclacel Pharmaceuticals (Nasdaq: CYCC)
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze